RT Journal Article
SR Electronic
T1 Bronchoscopic intratumoural therapies for non-small cell lung cancer
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 200028
DO 10.1183/16000617.0028-2020
VO 29
IS 156
A1 DeMaio, Andrew
A1 Sterman, Daniel
YR 2020
UL http://err.ersjournals.com/content/29/156/200028.abstract
AB The past decade has brought remarkable improvements in the treatment of non-small cell lung cancer (NSCLC) with novel therapies, such as immune checkpoint inhibitors, although response rates remain suboptimal. Direct intratumoural injection of therapeutic agents via bronchoscopic approaches poses the unique ability to directly target the tumour microenvironment and offers several theoretical advantages over systemic delivery including decreased toxicity. Increases in understanding of the tumour microenvironment and cancer immunology have identified many potential options for intratumoural therapy, especially combination immunotherapies. Herein, we review advances in the development of novel bronchoscopic treatments for NSCLC over the past decade with a focus on the potential of intratumoural immunotherapy alone or in combination with systemic treatments.Bronchoscopic intratumoural injection of novel therapies holds remarkable potential for targeted treatment of non-small cell lung cancer with a reduced risk of toxicities https://bit.ly/36xraX7